Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI258 in Advanced or Metastatic Melanoma
NCT00303251Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2006
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in melanoma, sponsored by Novartis. Primary endpoints: Maximum Tolerated Dose, Pharmacokinetics and 1 more. Started Apr 2006; status: completed.
02
Drugs
dovitinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00303251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303251.